Skip to content
To the full analysis

GlaxoSmithKline Pharmaceuticals Stock: Balance Sheet and Debt

GLAXO.NS
$29.43Closing price of 20 Nov 2026MEQIRI Score 74 out of 100

GlaxoSmithKline Pharmaceuticals has a debt to equity ratio of 0.01 and an interest coverage of over 100x.

Daily figure as of 22 Nov 2026

Debt / Equity
0.01
Interest coverage
> 100x
Current ratio
2.03
Cash & equivalents
$297.42M
Total assets
$466.56M
Equity ratio
52.4%
Goodwill and intangible assets
$707.45K
not split out
Net debt
−$293.83M
More cash than debt

Balance Sheet Over Time

In all 10 fiscal years since 2017 GlaxoSmithKline Pharmaceuticals held more cash than debt.

Total Assets and Equity Ratio

How large the balance sheet of GlaxoSmithKline Pharmaceuticals Limited is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2007$193.05M$454.86K$454.86K67.3%−$3.26M
2008$219.7M$4.55M$4.55M67.8%−$16.1M
2009$250.39M$4.55M$4.55M67.9%−$103.23M
2010$269.52Mnot reported separatelynot reported separately71.5%−$186.51M
2011$303.26Mnot reported separatelynot reported separately69.4%−$215.56M
2012$330.81M$4.55M$4.55M63.1%−$219.92M
2013$333.25Mnot reported separatelynot reported separately65.0%−$220.6M
2014$337.69Mnot reported separatelynot reported separately63.6%−$217.74M
2015$347.93Mnot reported separatelynot reported separately75.8%−$210.64M
2016$328.68Mnot reported separatelynot reported separately55.7%−$142.46M
2017$324.13M$3.48Mnot split out66.8%−$97.82M
2018$425.95M$7.84Mnot split out52.1%−$136.94M
2019$422.05M$7.07Mnot split out54.7%−$123.79M
2020$338.34M$5.35Mnot split out58.1%−$110.06M
2021$335.94M$4.68Mnot split out48.1%−$121.75M
2022$499.95M$3.72Mnot split out57.5%−$311.05M
2023$358.95M$3.68Mnot split out52.3%−$176.81M
2024$383.77M$2.54Mnot split out50.0%−$198.34M
2025$443.28M$1.44Mnot split out47.5%−$268.48M
2026$466.56M$707.45Knot split out52.4%−$293.83M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.

Equity and Debt

What the Company Owns and Owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2007$3.86M$130M$601.9K0
2008$16.72M$149M$628.53K0
2009$103.24M$170.01M$2.56K0
2010$187.09M$192.73M$586.11K0
2011$216.12M$210.58M$556.99K0
2012$220.45M$208.87M$529.29K0
2013$221.1M$216.54M$495.63K0
2014$218.19M$214.7M$446.98K0
2015$210.98M$263.73M$336.17K0
2016$142.72M$183.01M$256.06K0
2017$97.99M$216.55M$172.11K0
2018$137.05M$221.99M$106.72K0
2019$123.85M$230.9M$62.91K0
2020$114.58M$196.45M$4.51M0.02
2021$125.48M$159.51M$3.74M0.02
2022$313.22M$287.34M$2.17M0.01
2023$178.49M$187.89M$1.68M0.01
2024$200.36M$191.81M$2.01M0.01
2025$269.55M$210.55M$1.07M0.01
2026$297.42M$244.66M$3.59M0.01

Debt of Industry Peers

GlaxoSmithKline Pharmaceuticals's debt to equity is lower than that of 65 of 79 other stocks in the Healthcare sector.

StockDebt to equityEquity ratio
Daiichi Sankyo0.1841.6%
Orion0.2463.9%
Zhangzhou Pientzehuang Pharmaceutical.0.0785.9%
CSPC Pharmaceutical Group0.0274.0%
Grifols1.2638.6%
Ono Pharmaceutical0.1477.4%
GlaxoSmithKline Pharmaceuticals0.0152.4%
Organon11.705.8%
Virbac0.2658.8%

Figures from the latest fiscal year. The eight peers closest in market value, largest first.

Data and Required Disclosures

  • ; time horizon around 12 months
  • Rated Strong since 7 Nov 2026; valuation signal Overvalued since 22 Nov 2026
  • Price: closing price of 20 Nov 2026
  • Amounts in US dollars at the ECB reference rate of 20 Nov 2026 ($1 = ₹92.6752)
  • Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2026. MEQIRI calculates the score and fair value itself every night.
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy